Founder and Chief Executive Officer
Multiple Myeloma Research Foundation (MMRF)
Multiple Myeloma Research Consortium (MMRC)
Kathy Giusti is the Founder and Chief Executive Officer of the Multiple Myeloma Research Foundation (MMRF) and the Multiple Myeloma Research Consortium (MMRC). Giusti launched the MMRF in 1998, after her diagnosis with the incurable blood cancer multiple myeloma, followed by the MMRC in 2004. Leveraging her for-profit experience, she applied her business savvy to the science of cancer research and has helped to transform the culture of the traditional not-for-profit model. Her successful track record of building groundbreaking collaborative models underpinned by strong incentive structures to accelerate drug discovery and development has yielded meaningful returns for multiple myeloma patients. Further, committed to maximizing the patient-impact of these models, Giusti has shared her approach with many research organizations that are pursuing treatment advances for a number of cancers and other devastating diseases.
Prior to founding the MMRF, Giusti, a former pharmaceutical executive who began her career with Merck & Co, last served as Executive Director of G.D. Searle’s worldwide arthritis franchise. Giusti, a multiple myeloma patient, was named to the 2011 TIME 100 List of the world’s most influential people.
She has received many other awards for her leadership efforts, including the American Association for Cancer Research (AACR) Centennial Medal for Distinguished Public Service, the Harvard Business School Alumni Achievement Award, and the Healthcare Businesswomen’s Association’s Woman of the Year Award.
Additionally, she has been featured on the Today Show, CBS Evening News, CBS This Morning, CNN Money, Fox News and NBC Nightly News, as well as in The Wall Street Journal, The New York Times, The Economist, and TIME.
Giusti currently serves on the President’s Council of Advisors on Science and Technology, as an advisor to Stand Up to Cancer, and has previously served on the President’s National Cancer Advisory Board, the Board of Directors for IMS Health, and the Institute of Medicine’s National Cancer Policy Board. She received her MBA in general management from Harvard Business School and graduated from the University of Vermont magna cum laude with a Bachelor of Science in Biological Sciences.